In Pink Sheet, Shanghai Life Sciences Partner Quoted on China’s Proposed Amendments to Pharmaceutical Regulations
Life sciences partner Katherine Wang (Shanghai) was quoted in a Nov. 2 article published by The Pink Sheet examining the China Food and Drug Administration (CFDA) newly released registration proposals. The proposals indicate an intention on the part of CFDA to foster an environment that is conducive to innovation, and the proposals include reducing timelines for clinical trials and new drug review. Harsher penalties for individual violators are also put into place.
Ms. Wang notes that the CFDA’s proposed amendments will be more aligned with international regulatory practices and the revisions reflect discussions with the pharmaceutical industry.